Value Partners, Insilico Medicine Plan AI, Life Sciences CVC Fund
MT Newswires Live
Aug 19
Value Partners Group (HKG:0806), Insilico Medicine (HKG:3696), Shanghai Pudong Development Group, and Pudong Construction plan to jointly establish a RMB-denominated corporate venture capital fund.
The fund will focus on artificial intelligence and life sciences, according to a statement on Tuesday.
Value Partners' onshore private fund manager will serve as the fund's general partner and manager.
The parties plan to combine capital and industry resources to invest across the AI and life sciences ecosystem.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.